Literature DB >> 34284057

Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors.

Chunkyu Ko1, Jinpeng Su2, Julia Festag2, Romina Bester2, Anna D Kosinska3, Ulrike Protzer4.   

Abstract

The mouse is not a natural host of hepatitis B virus (HBV) infection and - despite engraftment of hepatocytes with the HBV receptor - does not support formation of HBV covalently closed circular (ccc) DNA serving as a template for viral transcription and permitting persistent infection. In a recent study, cccDNA formation in mouse hepatocytes has been described following an HBV genome delivery by a recombinant, adeno-associated virus vector (rAAV) (Lucifora et al., 2017). The integrity of HBV cccDNA, its origin and functionality, however, remained open. In this study, we investigated the identity, origin, and functionality of cccDNA established in mice infected with rAAV carrying 1.3-fold overlength HBV genomes. We show that replication of HBV genotypes A, B, C and D can be initiated in mouse livers, and that cccDNA derived from all genotypes is detected. Restriction enzyme and exonuclease digestion as well as sequencing analysis of cccDNA amplicons revealed authentic HBV cccDNA without any detectable alteration compared to cccDNA established after HBV infection of human liver cells. Mouse livers transduced with a core protein-deficient HBV using rAAV still supported cccDNA formation demonstrating that the genesis of cccDNA was independent of HBV replication. When mice were infected with an rAAV-HBV1.3 carrying premature stop codons in the 5' but not in the 3' core protein open reading frame, the stop codon was partially replaced by the wild-type sequence. This strongly indicated that intramolecular recombination, based on >900 identical base pairs residing at the both ends of the HBV1.3 transgene was the origin of cccDNA formation. Accordingly, we observed a constant loss of cccDNA molecules from mouse livers over time, while HBeAg levels increased over the first two weeks after rAAV-HBV1.3 infection and remained constant thereafter, suggesting a minor contribution of the cccDNA molecules formed to viral transcription and protein expression. In summary, our results provide strong evidence that intramolecular recombination of an overlength, linear HBV genome, but not HBV genome recycling, enables cccDNA formation in rAAV-HBV mouse models.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adeno-associated virus; Hepatitis B virus; Mouse liver; Recombination; cccDNA

Mesh:

Substances:

Year:  2021        PMID: 34284057     DOI: 10.1016/j.antiviral.2021.105140

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

1.  In Vivo Bioluminescence Imaging of HBV Replicating Hepatocytes Allows for the Monitoring of Anti-Viral Immunity.

Authors:  Katrin Manske; Annika Schneider; Chunkyu Ko; Percy A Knolle; Katja Steiger; Ulrike Protzer; Dirk Wohlleber
Journal:  Viruses       Date:  2021-11-13       Impact factor: 5.048

2.  In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors.

Authors:  Shonisani Wendy Limani; Njabulo Mnyandu; Abdullah Ely; Reubina Wadee; Anna Kramvis; Patrick Arbuthnot; Mohube Betty Maepa
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

Review 3.  Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics.

Authors:  Njabulo Mnyandu; Shonisani Wendy Limani; Patrick Arbuthnot; Mohube Betty Maepa
Journal:  Virol J       Date:  2021-12-13       Impact factor: 4.099

4.  A New Model to Assess Hepatitis B Virus Covalently Closed Circular DNA: A Window Into a Previously Hidden Space?

Authors:  Min Xu; Wenyu Lin; Raymond T Chung
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-01-25

Review 5.  Hepatitis B and circadian rhythm of the liver.

Authors:  Ivana Skrlec; Jasminka Talapko
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.